$7.4 Bil­lion Set­tle­ment With Purdue Pharma in Opi­oid Epidemic

Translate to Spanish or other 102 languages!

exas Attorney General Ken Paxton announced that a bipartisan coalition of states and other parties reached a $7.4 billion settlement in principle with members of the Sackler family and their company Purdue Pharma, Inc. (“Purdue”) for their instrumental role in creating the opioid crisis. Logo Source: Public Domain via Wikimedia Commons. Bad for illustration purposes
exas Attorney General Ken Paxton announced that a bipartisan coalition of states and other parties reached a $7.4 billion settlement in principle with members of the Sackler family and their company Purdue Pharma, Inc. (“Purdue”) for their instrumental role in creating the opioid crisis. Logo Source: Public Domain via Wikimedia Commons. Bad for illustration purposes
- Advertisement -

Texas Attorney General Ken Paxton announced that a bipartisan coalition of states and other parties reached a $7.4 billion settlement in principle with members of the Sackler family and their company Purdue Pharma, Inc. (“Purdue”) for their instrumental role in creating the opioid crisis. 

Purdue, under the Sacklers’ leadership, invented, manufactured, and aggressively marketed opioid products for decades, fueling waves of addiction and overdose deaths across the country. The settlement ends the Sacklers’ control of Purdue and their ability to sell opioids in the United States. Further, it will deliver funding directly to communities across the country over the next 15 years to support opioid addiction treatment, prevention, and recovery programs. The $7.4 billion settlement in principle, the nation’s largest settlement to date with individuals responsible for contributing to the opioid crisis, comes after the United States Supreme Court overturned a prior multistate settlement with the Sacklers and Purdue in June 2024.

“For years, I have aggressively worked to hold Purdue Pharma and other corporations accountable for their roles in creating and exacerbating the deadly opioid crisis that harmed so many Americans,” said Attorney General Paxton. “While nothing can restore the damage done, this settlement will provide Texans valuable resources to help prevent more opioid abuse. It was an honor to help lead these negotiations and I will never stop ensuring that justice is secured for those affected.” 

- Advertisement -

Attorney General Paxton has been a national leader in holding companies accountable for their roles in the opioid crisis, securing over $3 billion in settlements with Johnson & JohnsonWalmartWalgreensCVS, and other companies. 

Joining Attorney General Paxton in securing the settlement in principle are the attorneys general of California, Colorado, Connecticut, Delaware, Florida, Illinois, Massachusetts, New York, Oregon, Pennsylvania, Tennessee, Vermont, Virginia, and West Virginia.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

What to Know About the Cyclospora Parasite in Your Grocery Cart

You’ve probably seen the headlines about a parasite spreading across the United States and making people sick, but what exactly is causing it? 

STHS Children’s Free Food Safety Webinar for Parents on July 15th

Every meal should help children grow and thrive, not put their health at risk.

How Extreme Weather and Air Pollution Put Your Heart at Risk

It’s not just high temperatures that can put stress on the heart. Other environmental factors, such as air pollution, extreme cold, hurricanes, wildfires, and other climate events, can contribute to or worsen cardiovascular conditions.

Scientists Unlock Faster, Better Way to Capture Ultimate Cancer-Fighting Cells

A new platform developed by researchers at The University of Texas MD Anderson Cancer Center quickly finds and isolates rare, tumor-reactive immune cells that are especially good at recognizing and attacking cancer cells, even without knowing which tumor targets are recognized by the immune cells. This approach addresses a major bottleneck in immunotherapy development and could potentially accelerate the creation of personalized treatments.
- Advertisement -